Disease transformation
| Case . | Disease conversion . | Time to conversion (y) . | BCR-ABL+ . | Outcome after conversion . |
|---|---|---|---|---|
| 1 | AML | 12 | yes | Death in 3 mo |
| 2 | AML | 6 | no | Death in 2 mo |
| 3 | IM | 6 | no | Alive at 3 y |
| 4 | IM | 10 | no | Alive at 2 y |
| 5 | IM | 4 | no | Alive at 2 y |
| 6 | MDS | 9 | no | Alive at 6 mo |
| 7 | MG | 5 | no | Alive at 2 y |
| 8 | MG | 7 | no | Alive at 2 y |
| Case . | Disease conversion . | Time to conversion (y) . | BCR-ABL+ . | Outcome after conversion . |
|---|---|---|---|---|
| 1 | AML | 12 | yes | Death in 3 mo |
| 2 | AML | 6 | no | Death in 2 mo |
| 3 | IM | 6 | no | Alive at 3 y |
| 4 | IM | 10 | no | Alive at 2 y |
| 5 | IM | 4 | no | Alive at 2 y |
| 6 | MDS | 9 | no | Alive at 6 mo |
| 7 | MG | 5 | no | Alive at 2 y |
| 8 | MG | 7 | no | Alive at 2 y |
Cytogenetics at conversion for case 1: t(7;13)(q33;q13), inv(11)(p12;q24). Cytogenetics at conversion for cases 2-8 was unchanged.
AML, acute myeloid leukemia; IM, idiopathic myelofibrosis; MDS, myelodisplastic syndrome; MG, monoclonal gammopathy.